ENZON PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1981-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.enzon.com
Clinical Trials
17
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01337518
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇬🇧Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Study of EZN-2208 Pediatric Patients With Solid Tumors
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT01295697
- Locations
- 🇺🇸
Lia Gore, MD, Aurora, Colorado, United States
🇺🇸Suzanne Shusterman, MD, Boston, Massachusetts, United States
🇺🇸Rochelle Bagatell, MD (Principal Investigator), Philadelphia, Pennsylvania, United States
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer
- First Posted Date
- 2009-12-21
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT01036113
- Locations
- 🇺🇸
Location #12, Sedona, Arizona, United States
🇺🇸Location #5, Tucson, Arizona, United States
🇺🇸Location #32, Murrieta, California, United States
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2011-09-20
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00931840
- Locations
- 🇺🇸
Location #033, Tucson, Arizona, United States
🇺🇸Location# 042, Alhambra, California, United States
🇺🇸Location # 043, Bakersfield, California, United States
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
- Conditions
- InfectionLymphomaMyelodysplastic SyndromesNeutropeniaUnspecified Childhood Solid Tumor, Protocol SpecificLeukemiaFever, Sweats, and Hot Flashes
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Enzon Pharmaceuticals, Inc.
- Registration Number
- NCT00886496
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- Next